that Th17-enriched CCR6 ؉ cells expressed higher levels of ␣4␤7 and bound HIV envelope in an ␣4␤7-dependent manner. The cells also had greater expression of CD4 and CXCR4, but not CCR5, than CCR6 ؊ cells. Moreover, unlike Th1 cells, Th17 cells produced little CCR5 ligand, and transfection with one of the CCR5 ligands, MIP-1␤ (CCL4), increased their resistance against HIV. These results indicate that features unique to Th17 cells, including higher expression of HIV receptors and lack of autocrine CCR5 ligands, are associated with enhanced permissiveness of these cells to HIV.
T he main target of human immunodeficiency virus (HIV) infection is CD4 T cells, and their loss leads ultimately to AIDS. In recent years, a number of studies have focused on examining the specific T helper (Th) cell subsets affected by HIV infection. The loss of Th17 cells in particular has been implicated in HIV disease progression in humans and animal models. Th17 cells secrete interleukin 17 (IL-17) and other cytokines that play a critical role in maintaining mucosal integrity and control of bacterial and fungal infections (1) . Depletion of this specific Th subset has been shown to associate with increased translocation of bacterial products across the mucosal barrier, increased viral loads, and immune hyperactivation associated with HIV disease (2) (3) (4) . Notably, Th17 depletion was apparent even at the early stages of pathogenic simian immunodeficiency (SIV) infection of rhesus macaques but not in the disease-free infection of the natural hosts African green monkeys or sooty mangabeys (3, 5) . Depletion of Th17 cells during SIV infection in rhesus macaques was also associated with enhanced dissemination of Salmonella enterica serovar Typhimurium from intestinal mucosa to mesenteric lymph nodes (6) . Notably, the loss of Th17 cells occurring during pathogenic SIV infection was accompanied with increased numbers of Th1 cells and reduction of IL-21-producing Th (Th21) cells (2, 7) . Higher percentages of regulatory T cells (Treg) were also found in the gut mucosa of HIV-infected subjects and SIV-infected rhesus macaques (3, 4) . These data demonstrate significant alterations in the balance of different T cell subsets in the gut mucosal sites during HIV and SIV infection and suggest differential susceptibility of the distinct subsets to depletion by these viruses.
The extents to which HIV infection affects Th17 cells vis-à-vis other Th subsets in human patients require further investigation.
In an early study by Brenchley et al. (5) , the loss of Th17 cells was observed in the gut specimens but not in the peripheral blood or bronchoalveolar lavage from HIV-infected subjects, while the frequencies of Th1 cells in the three sites were not affected. In human cervical tissues, McKinnon et al. detected a subset of Th17 cells that were severely depleted in HIV-infected subjects (8) . Lower frequencies of Th17 and Th1 cells were reported in the peripheral blood of aviremic HIV ϩ subjects on antiretroviral therapy (ART), but those of ART-naive patients were comparable with uninfected healthy subjects (9) . More recently, depletion of CD4 Th17 with the CD90 marker and its imbalance relative to Treg was noted in untreated HIV-infected subjects compared to those in infected patients on ART and healthy controls (10) . Partial to full recovery of Th17 responses was also observed in some patients on ART (11) , although another study (12) found no difference in the frequencies of Th17 cells in the peripheral blood and colons from uninfected subjects, HIV ϩ subjects on ART, and HIV ϩ long-term nonprogressors. These data highlight the need for a controlled experimental system to study the effects of HIV and ART on human Th17 and other Th subsets and to understand the mechanisms that drive the alterations observed with these functional Th subsets during HIV infection.
In this study, we compared the proportion of Th17 and Th1 cells in the peripheral blood of healthy, uninfected donors and HIV-infected patients with CD4 counts of Ͼ500 and low to undetectable viremia. Since a significant reduction of Th17 cells, but not Th1 cells, was observed among HIV-infected subjects, we sought to understand the reasons for preferential depletion of Th17 over Th1 cells using an in vitro system of primary human CCR6 ϩ CD4 T cells. This culture system allowed vast expansion of the Th17 proportion beyond the 1 to 2% normally found circulating in the peripheral blood, such that both Th17 and Th1 cells are present at high frequencies within the same culture. With this system, the greater loss of Th17 cells than Th1 cells was found to correlate with higher susceptibility of Th17 cells to HIV infection and cell death. Both CCR5-tropic and CXCR4-tropic HIV preferentially targeted Th17 cells. Subsequently, we evaluated cellular determinants that contribute to increased Th17 susceptibility to infection and depletion. As increased Th17 targeting was apparent at the early stages of viral envelope binding and entry, differential expression of the viral receptors CD4, CCR5, CXCR4, and ␣4␤7 was evaluated in Th17-enriched and Th17-depleted CD4 T cell populations. Furthermore, since Th17 cells from the peripheral blood and the intestinal mucosa do not express CCR5 ligands MIP-1␣ (CCL3), MIP-1␤ (CCL4), and RANTES (CCL5), known to be potent mediators of self-protection against HIV, we transfected Th17-enriched cells with MIP-1␤ (CCL4) and assessed their resistance to HIV entry. The data demonstrate that increased permissiveness of Th17 cells, relative to Th1 cells, to infection by CCR5-tropic and CXCR4-tropic HIV isolates correlates with higher expression of the HIV envelope receptors CD4, CXCR4, and ␣4␤7, coupled with deficiency in autocrine CCR5 ligand expression.
MATERIALS AND METHODS

Cells.
Peripheral blood and rectal biopsy specimens were obtained from consented HIV-seropositive and -seronegative donors at the NYU Langone Blood Center and the VA New York Harbor Healthcare System-Manhattan Campus under a protocol approved by the Institutional Review Board of the VA New York Harbor Healthcare System. Written informed consent was provided by each study participant. HIV ϩ subjects were asymptomatic chronically infected individuals with undetectable to low viral loads (Ͻ75 to 1,576 viral RNA [vRNA] copies/ml), except for one individual with a viral load of 38,165 copies/ml. The subjects were selected based on CD4 counts of Ͼ500 cells/l. Three subjects were on ART for 3 to 4 years, while the remaining six subjects' ART information was not available. Twenty-six HIV-seronegative subjects were also recruited for this study. Peripheral blood mononuclear cells (PBMCs) from these seronegative donors were tested ex vivo or used to generate CCR6 ϩ and CCR6 Ϫ CD4 T cell cultures. PBMCs were isolated from whole blood with Histopaque-1077 (Sigma, St. Louis, MO) density gradient centrifugation. CD4 T cells were enriched with the Untouched CD4 T cell enrichment kit (Invitrogen, Dynal AS, Oslo, Norway). Sorting of CCR6 ϩ and CCR6 Ϫ T cells was done with a FACSAria cell sorter at the NYU Flow Cytometry Core Facility. Two additional HIV-seronegative subjects were recruited to obtain rectal biopsy specimens. Eight to 10 pinch biopsy specimens were collected from the sigmoid colon and subsequently treated with collagenase VIII (Sigma, St. Louis, MO) and DNase 1 (Sigma, St. Louis, MO). Lymphocytes were then isolated with Percoll (GE Healthcare Bioscience, Sweden) gradient centrifugation.
Cell culture and virus infection. Sorted CCR6 ϩ and CCR6 Ϫ CD4 T cells were stimulated in 24-well plates precoated with anti-CD3 and anti-CD28 (eBioscience, San Diego CA), 2 g/ml each, in complete medium consisting of RPMI (Lonza, Walkersville, MD), 10% fetal bovine serum (HyClone, South Logan, UT), 2 nM L-glutamine, and 50 U/ml penicillinstreptomycin (Lonza, Walkersville, MD) plus 10 ng/ml of each IL-1␤ and IL-23 (eBioscience, San Diego, CA). After 3 days, 20 U/ml IL-2 (Roche, Germany) was added to expand the CCR6 ϩ and CCR6 Ϫ cells. For infection experiments, the cells were infected on day 3 with HIV and assessed for cytokine and gag p24 expression 5 to 7 days later. Viruses tested were BX08 (CCR5 tropic, subtype B), DJ263 (CCR5 tropic, subtype A), 97ZA009 (CCR5 tropic, subtype C), BZ167 (dual tropic, subtype B), and MN (CXCR4 tropic, subtype B) isolated from chronic infection and expanded in PBMCs to yield p24 concentrations of approximately 10 to 100 ng/ml. Molecular clone CCR5-tropic pWITO.c/2474 from an acutely subtype B-infected donor (Fiebig stage II) residing in the United States was also used (13) ; this virus was expanded by transfection in 293T cells following a similar protocol in a previous manuscript (14) . Viruses were concentrated for 1 h at 15,550 rpm at 4°C in an ultracentrifuge (Mikro 22R Hettich; Zentrifugen) prior to the addition to cells.
Intracellular cytokine staining. Cells were stimulated with phorbol myristate acetate (PMA) (5 ng/ml) and ionomycin (1 g/ml) (Sigma, St. Louis, MO) for 5 h. Brefeldin A (10 g/ml) (Sigma, St. Louis, MO) was added during the last 3 h. Cells were washed, fixed with 1% paraformaldehyde (PFA), and permeabilized with Cytofix/Cytoperm (BD Biosciences, San Diego, CA) by following the manufacturer's protocol. Antibodies used for staining were CD3-allophycocyanin (APC)-Cy7, CD8 -PerCP-Cy5. Virus entry assay. Virus was generated by cotransfection of 293T cells with pWITO.c/2474 and Vpr-␤-lac at a 3:1 ratio (15) . Stimulated CCR6 ϩ and CCR6 Ϫ T cells were spinoculated with the virus for 1 h at 1,000 rpm at room temperature (RT), followed by incubation at 37°C for 1 h. Cells were then washed with cold Hanks balanced salt solution (HBSS) (Gibco/Invitrogen, Grand Island, NY) and stained with CCF2 (Invitrogen, Carlsbad, CA) for 3 h at RT according to the manufacturer's protocol. Fluorescence was detected in the AM-Cyan (uncleaved CCF2) and Pacific Blue (cleaved CCF2) channels in the FACSAria cell sorter (Beckman Dickinson). Data analysis was done with FlowJo 7.6.5.
Cell death assay. After 5 days of culture, cells infected with virus or left uninfected were washed with RPMI and incubated with fluorescently tagged peptides: 6-carboxyfluorescein (FAM)-YVAD-FMK and DEVD-FMK, which bind activated caspase 1 (ImmunoChemistry Technologies, Bloomington, MN) and caspase 3 (eBioscience, San Diego, CA), respectively, according to the manufacturers' protocols. Fluorescence was detected in a FACSCalibur (Beckman Dickinson), and data were analyzed with FlowJo 7.6.5.
Virus receptor staining. Antibodies used were CD4-FITC, CXCR4-PE, CCR5-APC, ␣4-PE, or ␤7-APC (BD Biosciences, San Diego, CA). To detect total expression, cells were fixed and permeabilized with Cytofix/ Cytoperm (BD Biosciences, San Diego, CA) prior to staining. Acquisition was done with FACSCanto and analysis with FlowJo 7.6.5. gp120 binding assay. Biotinylated 205F gp120 month 0 (founder) and month 59 (chronic) Env4.1 were previously described in reference 16; these CCR5-tropic envelope proteins were derived from virus isolates of a subtype C-infected patient, 205F (17) . Cells were incubated for 30 min with biotinylated gp120, 2 g in a buffer containing 10 mM HEPES (Sigma St. Louis MO), 150 mM NaCl, 1 mM MnCl 2 , and 100 M CaCl. After one wash, streptavidin-PerCP (BD Biosciences, San Diego, CA) was added to the cells. Blocking with antibody was done with 5 g of CD4 antibody (Clone:Leu3a; eBioscience, San Diego, CA) or 0.2 g of ␤7 antibody (Clone:FIB504; BD Biosciences, San Diego, CA). Soluble CD4-Fc was also tested by incubating 20 g of this protein with gp120 for 3 h at 37°C, prior to adding the mixture to the cells. CD4-Fc reactivity with the gp120 protein was confirmed in enzyme-linked immunosorbent assay (ELISA) (data not shown). Acquisition was done in a FACSCalibur, and data were analyzed in FlowJo 7.6.5. ccl4 transfection. A construct consisting of the ccl4 gene cloned into pIRES-Red (Clontech) was made by Biomatik. Cells were transfected using the Amaxa T cell transfection kit (Lonza, Koln, Germany) in a Nucleofector II (Lonza), program T023. About 16 to 20 h after transfection, cells were analyzed for dsRED expression and then used in virus entry assay. Expression of MIP-1␤ was also detected in the supernatant by ELISA (R&D Systems, Minneapolis, MN).
Statistics. Statistical analysis was done with unpaired or paired twotailed t tests using GraphPad Prism version 5.
RESULTS
Depletion of Th17 cells, but not Th1 cells, in the peripheral blood of chronically HIV-infected subjects.
To determine the extent to which HIV infection affects distinct Th subsets in peripheral blood, we compared the relative proportions of CD4 T cells producing IL-17A, IFN-␥, TNF-␣, and MIP-1␤ in HIV-seropositive and -seronegative individuals. All HIV ϩ subjects were asymptomatic, chronically infected individuals with CD4 counts of Ͼ500 cells/l who, except for one, had undetectable or low viral loads. PBMCs were stimulated with PMA and ionomycin, and CD4 T cells producing cytokines were detected by intracellular cytokine staining. The frequencies of CD4 T cells responding to PMA and ionomycin varied greatly among individual subjects and were not different between infected and uninfected subjects (range, 9 to 51% and 3 to 32% of total CD4 T cells, respectively). However, among the responding cells, the relative proportion of cells expressing each cytokine or chemokine revealed a distinct pattern in that IL-17A ϩ CD4 T cell levels were significantly lower in HIV ϩ subjects than in uninfected subjects (Fig. 1A ). This loss was specific for the IL-17A ϩ subset, as the number of CD4 T cells producing IFN-␥, TNF-␣, or MIP-1␤ from these same donors was comparable or slightly higher in HIV ϩ subjects. Dot plots in Fig.  1B from a representative uninfected subject show that IL-17A and IFN-␥ were expressed exclusive of one another, although a small population was positive for both IL-17A and IFN-␥, similar to the Th1/Th17 subset reported previously (18) . The vast majority of IL-17A ϩ CD4 T cells were also negative for MIP-1␤, but 40% were positive for TNF-␣. Both IL-17A ϩ TNF-␣ ϩ cells and IL-17A ϩonly cells were reduced in infected subjects ( Fig. 1A and data not shown). In contrast, most IFN-␥ ϩ CD4 T cells expressed MIP-1␤, TNF-␣, or both, and these populations were not reduced in the infected subjects ( Fig. 1A and B ). These data demonstrate selective loss of IL17A ϩ CD4 T cells, but not CD4 T cells producing IFN-␥, TNF-␣, and MIP-1␤, in the peripheral blood of chronically HIVinfected subjects, even with low or undetectable viremia.
Preferential infection of Th17 cells by HIV.
To better understand the differential effects of HIV infection on Th17 and Th1 subsets, we established an in vitro system in which both Th17 and Th1 cells were present in significant numbers in the same culture. CCR6 ϩ CD4 ϩ T cells were sorted from the peripheral blood of HIV-seronegative healthy donors, stimulated with anti-CD3 and anti-CD28 monoclonal antibodies (MAbs) in the presence of IL-1␤ and IL-23 for 3 days, and expanded with IL-2 for 5 days or more. Data from a representative culture show that 31% of the cells were IL-17A ϩ , 15% were IFN-␥ ϩ , and 22% were IL-17A ϩ IFN-␥ ϩ ( Fig. 2A) . A similar pattern was seen with cultures from all six donors tested ( Fig. 2B ). For comparison, parallel cultures of CCR6 Ϫ CD4 ϩ cells from the same donors had few IL-17A ϩ and IL-17A ϩ IFN-␥ ϩ cells, although IFN-␥ ϩ cells grew robustly ( Fig.  2A and B ). Hence, in the CCR6 Ϫ CD4 ϩ cultures, IFN-␥ ϩ cells were expanded and IL-17A ϩ cells were depleted, whereas in the CCR6 ϩ CD4 ϩ cultures, IL-17A ϩ and IL-17A ϩ IFN-␥ ϩ cells were enriched along with IFN-␥ ϩ cells. This in vitro system allows comparison of the distinct cell subsets within the same cultures, as well as Th17-enriched and Th17-depleted cultures from the same donors.
To evaluate the effects of HIV infection on Th17 and Th1 cells, the CCR6 ϩ CD4 ϩ cultures were infected with HIV or left uninfected for 5 days, and the percentages of IL-17A ϩ , IFN-␥, and virus gag p24 ϩ cells in the cultures were measured. As much as 30% of cells in the uninfected culture from one of the donors produced IL-17A, and 44% produced IFN-␥. In the parallel culture infected with HIV, the IL-17A ϩ cells decreased to 12%, and the IFN-␥ ϩ cells increased to about 52% of the total CD4 T cells (Fig. 3A) . The loss was apparent in both IL-17A ϩ IFN-␥ Ϫ and IL-17A ϩ IFN-␥ ϩ populations but not in the IFN-␥ single-positive population (Fig. 3B ). These data recapitulate the findings in Fig. 1 showing selective depletion of IL-17A ϩ cells and not IFN-␥ ϩ cells in PBMCs of HIV ϩ subjects ex vivo. Notably, the loss of IL-17A ϩ IFN-␥ Ϫ and IL-17A ϩ IFN-␥ ϩ cells correlated with greater proportions of infected p24 ϩ cells in these two cell populations (40% and 40%, respectively) than in the IFN-␥ single-positive population (2.7% p24 ϩ ) ( Fig. 3C ). These results demonstrate that HIV infection induces selective loss of IL-17A ϩ cells over IFN-␥ singlepositive cells, and the depletion is associated with greater susceptibility of the IL-17A ϩ cells to HIV infection. Figure 4A shows that higher rates of infection in IL-17A ϩ cells than in IFN-␥ ϩ cells were observed with CCR5-tropic, CXCR4tropic, or dual-tropic HIV isolates from chronic infection. This pattern was seen with cultures of unfractionated CD4 T cells or CCR6 ϩ CD4 ϩ -sorted cells from different donors ( Fig. 4A and B ). An infectious molecular clone, CCR5-tropic WITO.c/2474, from early/acute infection (13) was also tested. Infection with this isolate also depleted the IL-17A ϩ cells in the cultures from the majority of donors, whereas the effects on IFN-␥ ϩ cells were minimal ( Fig. 4C ). Subsequently, we asked whether Th17 cells were preferentially targeted at the entry stage using a virus-entry assay with WITO.c/2474 bearing ␤-lactamase-Vpr (Vpr-Blam). Virus entry was detected by cell staining with CCF2-AM (15) . For this assay, the level of virus entry in Th17-enriched CCR6 ϩ cells was compared to that in Th17-depleted CCR6 Ϫ CD4 T cells 2 h after virus incubation with the cells. Virus entry was detected in 4% of the CCR6 ϩ cells and Ͻ1% of the CCR6 Ϫ cells (Fig. 4D) . For control, a CCR5 antagonist, TAK779, was added and virus entry was reduced to a background level. Data from independent experiments with different donors showed consistently greater levels of virus entry into Th17-enriched CCR6 ϩ than into Th17-depleted CCR6 Ϫ CD4 T cell subsets (Fig. 4E) . Altogether, these data dem-onstrate that Th17 cells are preferentially infected and depleted by HIV-1 isolates from early and chronic infection.
Increased cell death in Th17-enriched CCR6 ؉ CD4 T cell cultures infected with HIV. Given that the Th17-enriched CCR6 ϩ CD4 T cell subset was highly permissive for HIV infection, we asked whether after infection these cells were also prone to cell death via apoptosis or pyroptosis. CCR6 ϩ and CCR6 Ϫ CD4 T cells were isolated, activated, and infected with HIV. On day 5, expression of activated caspase 3 (apoptosis marker) and activated caspase 1 (pyroptosis marker) was measured in infected and uninfected cultures from the same donor. We observed a significant increase in the percentage of cells bearing high levels of activated caspase 3 in the infected CCR6 ϩ cells compared to that in uninfected CCR6 ϩ cells (Fig. 5A) . In contrast, expression of activated caspase 3 in the uninfected and infected CCR6 Ϫ cells was similar. The same results were seen in cultures from multiple donors (Fig.  5B ). There was also a trend of higher numbers of cells with high activated caspase 1 expression in infected CCR6 ϩ cultures than in uninfected CCR6 ϩ , infected CCR6 Ϫ , and uninfected CCR6 Ϫ cultures from the same donors (Fig. 5C ). These results demonstrate that HIV infection of CCR6 ϩ cells results in increased cell death by both apoptotic and pyroptotic mechanisms.
Higher levels of HIV receptor expression and HIV envelope gp120 binding in Th17-enriched CCR6 ؉ CD4 T cells. To determine the cellular factors associated with preferential infection of Th17 cells over Th1 cells, we first evaluated expression of HIV receptors on these cells at the time of virus exposure. Th17-enriched CCR6 ϩ and Th17-depleted CCR6 Ϫ cells were treated with anti-CD3 and anti-CD28 MAbs, IL-1␤, and IL-23 and stained on day 3 with antibodies to CD4, CCR5, CXCR4, ␣4, and ␤7. Expression levels of CD4 (total and surface), CXCR4, ␣4, and ␤7 were markedly higher in the CCR6 ϩ cells than in the CCR6 Ϫ cells (Fig.  6A and B ). CCR6 ϩ cells had a slightly higher expression of CCR5 than CCR6 Ϫ cells did, but the differences did not reach statistical significance ( Fig. 6A and B ). Assessment of receptor expression was not performed on Th17 and Th1 cells as defined by their subset-defining cytokine markers, because cellular activation to induce production of these cytokines causes alteration of the receptor expression (data not shown) (19) (20) (21) (22) . When CCR6 ϩ and CCR6 Ϫ cells freshly isolated ex vivo from PBMCs were evaluated, no difference was seen with CD4 expression, while CCR5 levels were too low to compare (data not shown). However, higher levels of integrin ␤7 were reported among CXCR3 ϩ CCR6 ϩ Th17/Th1 cells ex vivo from the peripheral blood than from the other Th subsets (18) .
To evaluate whether increased expression of the HIV receptors on CCR6 ϩ cells leads to increased binding of HIV envelope gp120 to CCR6 ϩ cells compared to CCR6 Ϫ cells, activated CCR6 ϩ and CCR6 Ϫ T cells were incubated with recombinant gp120 proteins from early (month 0) and later (month 59) stages of HIV infection for 30 min at 4°C. Both subsets bound gp120 proteins, but the binding to CCR6 ϩ cells was greater than that to CCR6 Ϫ cells (Fig.  6C) . Experiments with gp120 from early and later stages of infection using cells from multiple donors yielded similar results (Fig.  6D) , demonstrating higher levels of HIV envelope gp120 attachment to CCR6 ϩ cells, consistent with preferential targeting and infection of this CD4 T cell subset by HIV. To delineate the contribution of the different receptors, we assessed the blocking effects of antibodies against CD4 and ␣4␤7. Treatment with anti-CD4 Leu3a had no effect (Fig. 6E ). Pretreating gp120 with soluble CD4-IgG also caused little change, although gp120 binding to CD4-IgG was demonstrated by ELISA (data not shown). In contrast, addition of the anti-␤7 antibody reduced gp120 binding, albeit not completely. This effect was observed with cells from different donors tested in independent experiments (Fig. 6E) . These results demonstrate that HIV envelope gp120 binds to activated CCR6 ϩ CD4 T cells to a greater extent than to the CCR6 Ϫ counterparts, and the enhanced binding is facilitated in part through the integrin ␣4␤7.
Lack of CCR5 ligand synthesis by Th17 cells. As the CCR5 receptor levels were only slightly higher on Th17-enriched CCR6 ϩ CD4 ϩ cells than on Th17-depleted CCR6 Ϫ CD4 ϩ cells, we next evaluated whether different expression of the CCR5 ligands in Th17 and Th1 subsets might account for greater susceptibility of Th17 cells to CCR5-tropic HIV isolates. Autocrine production of these chemokines has been shown to increase resistance of CD4 T cells against CCR5-tropic HIV infection (23, 24) . We measured coexpression of MIP-1␤ or MIP-1␣ with IL-17A and IFN-␥ in unfractionated PBMCs and gut mucosal lymphocytes treated with PMA-ionomycin. Figures 7A and B show that the vast majority of IL-17A ϩ cells in the peripheral blood did not express MIP-1␤ or MIP-1␣, in agreement with our initial observation in Fig. 1B . In contrast, about 50% of the IFN-␥-producing cells were positive for MIP-1␣ and MIP-1␤. Similarly, only a small percentage of IL-17A ϩ CD4 T cells from the gut mucosa were MIP-1␤ ϩ , while about half of IFN-␥ ϩ cells were also MIP-1␤ ϩ (Fig. 7C and D) . Because MIP-1␣ and MIP-1␤ were coexpressed (data not shown), we tested only one of them in subsequent experiments.
To assess whether autocrine production of CCR5 ligands by CD4 T cells preserved the cells during HIV infection, we infected activated CCR6 ϩ CD4 T cells with HIV and measured changes in the proportions of cell subsets producing or not producing MIP-1␣ compared to those in uninfected cells from the same donors. As seen in Fig. 8A , only a small fraction of IL-17A-producing cells in a CCR6 ϩ CD4 T cell culture were positive for MIP-1␣. With HIV infection, IL-17A-producing cells decreased whether they were positive or negative for MIP-1␣, but the decline of IL-17A ϩ cells positive for MIP-1␣ (6% to 4%) was not as great as that of MIP-1␣-/IL-17A ϩ cells (25% to 9%). In contrast, HIV infection increased the percentage of MIP-1␣ ϩ IFN-␥ ϩ by 1.5-fold over that of the uninfected control (25% to 37%) (Fig. 8A) , whereas the percentage of MIP-1␣ Ϫ IFN-␥ ϩ declined by about half (9% to 5%). This pattern was observed with all three donors tested, except one where IFN-␥ ϩ MIP-1␣ Ϫ cells slightly increased upon HIV infection (Fig. 8B) . These results corroborate published data that the capacity of CD4 T cells to produce CCR5 ligands offers survival advantage and that the CCR5 ligand-producing CD4 T cell subsets become the predominant population during HIV infection (24) (25) (26) (27) (28) .
Although high numbers of IFN-␥ ϩ Th1 cells capable of secret- ing CCR5 ligands were present together with Th17 cells within the same CCR6 ϩ cultures, they did not confer much antiviral protection to the neighboring Th17 cells via the paracrine mode. To confirm the importance of autocrine CCR5 ligand production by individual CD4 T cells for self-protection against HIV, we provided CCR5 ligands in cis to CCR6 ϩ cells by transfection with ccl4, which encodes one of the CCR5 ligands: MIP-1␤. At 17 to 20 h, an ϳ20% transfection rate was achieved and intracellular MIP-1␤ expression was increased by 2-to 5-fold, although the concentration of MIP-1␤ in the supernatants was merely 0.6 ng/ml. The cells were then treated with HIV-1 WITO.c/2474 bearing Vpr-Blam. Virus entry assessed at 2 h after exposure showed that 1.91% of infected cells were present among the CCR6 ϩ cells transfected with the vector control, while only 0.35% were detected in cells transfected with ccl4 (Fig. 8C) . Similar results were obtained from three independent experiments with different cell donors (Fig.  8D) . These data demonstrate that autocrine MIP-1␤ expressed by transfected CCR6 ϩ cells provided potent self-protection against HIV infection. Hence, in addition to higher levels of viral receptors CD4, CXCR4, and ␣4␤7, the lack of autocrine CCR5 ligand synthesis also increases HIV susceptibility of the Th17-enriched CCR6 ϩ T cell subset over the Th17-depleted CCR6 Ϫ T cells. The combina-tion of these factors correlates with preferential targeting and depletion of Th17 cells by HIV isolates with different coreceptor tropisms.
DISCUSSION
This study evaluated the differential effects of HIV infection on Th17 and Th1 cells and defined the factors associated with preferential depletion of Th17 cells over Th1 cells during HIV infection. The data demonstrate that the proportion of peripheral Th17 cells in chronically HIV-infected subjects was low relative to that of Th1 cells, although the patients had controlled viremia and CD4 counts of Ͼ500 cells/l. These results are consistent with our previous studies showing that virus suppression with antiretroviral drug was not sufficient to restore the Th17 cells in chronically HIV-infected CD4 T cell cultures (28) . However, a combination of antiretroviral drug and Th17 differentiating cytokines was effective to expand Th17 cells in the face of established HIV infection (28) . Other studies also showed that while Th17 cells could be induced early in response to acute HIV infection, these cells gradually declined in the course of HIV disease (29) . After ART, full restoration of total CD4 T cells and Th17 cells was not observed in all human patients and SIV-infected macaques (11, 30, 31) .
To understand better the differential effects of HIV infection on Th17 and Th1 subsets, we established an in vitro culture system with sorted CCR6 ϩ CD4 T cells, which upon activation in the presence of Th17 proliferation and survival cytokines IL-1␤ and IL-23 yielded an enriched population of IL-17A ϩ Th17 cells while also retaining the IFN-␥ ϩ Th1 cells. This enabled us to monitor HIV infection in these two distinct Th subsets simultaneously within the same cultures. The data demonstrate that IL-17A ϩ IFN-␥ Ϫ Th17 cells were preferentially infected and depleted by CCR5-tropic or CXCR4-tropic HIV isolates over IL-17A Ϫ IFN-␥ ϩ Th1 cells. A population of double-positive (IL-17A ϩ IFN-␥ ϩ ) cells was also present in the cultures and was targeted by HIV to the same extent as the single-positive IL-17A ϩ cells. These results were in accord with our previous findings with unfractionated CD4 T cells (28) and recapitulated the dramatic loss of Th17 response compared to Th1 response reported in HIV-infected patients and in SIV/macaque models ( Fig. 1) (2, 3, 5, 7) . The data also agree with published findings suggesting greater permissiveness of Th17 cells to HIV infection than other Th subsets (8, 9, 18, 32) , albeit without direct evidence as presented here. We further showed for the first time that HIV isolates from acute HIV infection displayed the same preference for targeting Th17-enriched CCR6 ϩ cultures as for Th17-depleted CCR6 Ϫ cultures, which was evident within 2 h after virus exposure to the cells. Moreover, we detected higher levels of the viral envelope gp120 binding to Th17enriched CCR6 ϩ cells than to Th17-depleted CCR6 Ϫ cells. All of these data indicate that increased susceptibility of Th17 cells to HIV infection occurs at the initial stages of virus-cell interaction. We examined if differential expression levels of HIV receptors on Th17 and Th1 cells could account for higher permissiveness of Th17 cells to HIV infection. CCR5 expression varies among different T cell subsets and is modulated upon T cell activation (18, 33, 34) . For examples, gut-associated lymphocytes have higher expression of CCR5 and CXCR4 than cells in the peripheral blood (35) . However, surface CCR5 levels were comparable on peripheral Th17 and Th1 cells defined as CCR4 ϩ CXCR3 Ϫ CCR6 ϩ and CCR4 Ϫ CXCR3 ϩ CCR6 Ϫ , respectively, and were only slightly higher on CCR4 Ϫ CXCR3 ϩ CCR6 ϩ Th1/Th17 cells (18) . In this study, we measured both surface and intracellular CCR5 expressed by cells in Th17-enriched CCR6 ϩ and Th17-depleted CCR6 Ϫ cultures, and no significant difference was detected. Yet, it remains possible that Th1 and Th17 cells display different levels of ligand-bound and unbound CCR5 which were indistinguishable by antibodies used in this study, since these Th cells differ in the ability to synthesize autocrine CCR5 ligands.
In contrast to CCR5, higher levels of CD4, CXCR4, and ␣4␤7 were observed on Th17-enriched CCR6 ϩ cells than on Th17-de- pleted CCR6 Ϫ cells. These differences were observed at the time of virus exposure (3 days after cell activation) and correlated with higher gp120 binding. Whether CD4 and ␣4␤7 are present as complexes on CCR6 ϩ cells, as previously reported for retinoic acid-treated CD4 T cells (36) , remains to be determined, but antibody blocking experiments show that only antibody to ␤7 reduced HIV envelope gp120 binding, indicating that the specific affinity of gp120 for ␣4␤7 provides a mechanism for HIV to target CCR6 ϩ cells. Of note, both CCR6 ϩ and CCR6 Ϫ cells were expanded under the same culture condition to yield high numbers of IFN-␥ ϩ cells, but only the CCR6 ϩ cultures contained IL-17A ϩ cells. Hence, the significant differences in receptor expression and gp120 binding between these two cultures were associated with enrichment versus depletion of IL-17A ϩ cells. It should also be mentioned that although the CCR6 Ϫ cells freshly isolated ex vivo from the peripheral blood contained a mixture of memory and naive CD4 T cell populations, after activation under the conditions used in this study (CD3/CD28 antibodies plus IL-1␤, IL-23, and IL-2), most cells displayed the CD45RO ϩ CD45RA Ϫ memory phenotype, like their CCR6 ϩ counterparts (data not shown). Nonetheless, the possibility remains that the surface phenotypes of Th17 and Th1 cells, as defined in our in vitro system, may not fully represent those found in vivo, particularly in the mucosal or lymphoid tissues targeted by HIV.
In this study, HIV-1 envelope proteins from both early and chronic stages of infection displayed greater binding to CCR6 ϩ CD4 T cells than to CCR6 Ϫ CD4 T cells. In the past study, envelope proteins from the early transmitting isolates were found to have preferential binding to ␣4␤7, and those from chronic infection mediated stronger binding to CD4 than ␣4␤7, but the CD4 T cells had been activated and cultured in retinoic acid rather than with Th17 expansion/survival cytokines used here (16) . Indeed, retinoic acid treatment has been shown to favor differentiation of Treg cells and inhibit Th17 cell generation (37) . Moreover, when treated with retinoic acid, CCR6 ϩ cells were equally permissive to HIV regardless of ␣4␤7 expression, and increased susceptibility of these cells was attributed to CCR5 upregulation (38) . On the other hand, when Monteiro et al. evaluated IL-17A synthesis in peripheral CCR6 ϩ cells with or without ␤7 expression, higher percentages of Th17 cells were found among the ␤7 ϩ CCR6 ϩ cells than among the ␤7 Ϫ CCR6 Ϫ cells (38) , as similarly observed with the in vitro-stimulated cells in this study. Remarkably, a population of cervical Th17 cells, the types of cells that most likely encounter virus at the primary site of infection by sexual route, also expressed ␣4␤7, and gp120 binding to cervical T cells was blocked with a combination of anti-CD4 and EDTA, which disrupts integrin binding, but not with antibody to CD4 alone (8) . Hence, CCR6 ϩ Th17 cells are a preferred target of HIV, and this is associated with their enhanced expression of virus receptors, including the gp120capturing integrin ␣4␤7.
Previous findings of Monteiro et al. (38) showed high Ki67 expression among the CCR6 ϩ CD4 ϩ T cell subset. Dillon et al. (39) also found that, among lamina propria lymphocytes, IL17A ϩ Th17 and IL-17A ϩ IFN-␥ ϩ Th1/Th17 cells proliferated more than IFN-␥ ϩ Th1 cells and supported more productive HIV infection. These findings suggest that Th17 cells have an increased propensity to proliferative and thus provide a more favorable environment for HIV replication than Th1 cells. Evidence demonstrating enhanced rates of virus replication and progeny virus production in Th17 cells compared to those in Th1 cells is not yet available.
Rather, our data from the gp120 binding assay and virus entry experiment supports the notion that enhanced targeting of Th17enriched CCR6 ϩ cells by HIV occurs at the early stages of virus attachment and entry to the cells. This idea is also consistent with our findings showing higher expression levels of the virus receptors and particularly the integrin ␣4␤7, which is not required for HIV infection but may promote virus binding to the cells prior to infection and replication, on Th17-enriched CCR6 ϩ cells than on Th17-depleted CCR6 Ϫ cells.
Another cellular factor known to modulate susceptibility of CD4 T cells is autocrine production of CCR5 ligands (25, 40) . While T cell activation is typically required for robust HIV infection, previous studies have shown that activated CD4 T cells secreting CCR5 ligands are able to thwart infection by CCR5-tropic HIV (23, 41) . However, only a fraction (ϳ50%) of Th1 cells is capable of producing CCR5 ligands MIP-1␣ or MIP-1␤, and most of Th17 cells do not produce these chemokines. No ccl5 (rantes) mRNA was detected in these Th17 cells either (9) . In our study, only a very small percentage of IL-17A ϩ cells were found to make MIP-1␣ or MIP-1␤, while as much as 50% of IFN-␥ ϩ cells synthesized these chemokines. This was observed equally with cells from peripheral blood and gut mucosa. CXCR4 ligand SDF-1, on the other hand, was not expressed by either Th1 or Th17 (data not shown). Among IL-17A ϩ MIP-1␣ ϩ cells, only a fraction of the cells were also positive for IFN-␥ (data not shown), indicating that this population is not identical to the IL-17A ϩ IFN-␥ ϩ Th1/Th17 cells. Interestingly, following HIV infection, IFN-␥ ϩ MIP-1␣ ϩ cells significantly increased in proportion, while IFN-␥ ϩ MIP-1␣ Ϫ cells declined, similar to IL-17A ϩ cells that lacked MIP-1␣. Favre et al. also reported that the frequency of MIP-1␤ ϩ T cells increased in the blood after pathogenic SIV infection of macaques (3) . Notably, although our culture system had a significant number of Th1 cells producing CCR5 ligands, the CCR5 ligands secreted into the supernatant were not sufficient to protect Th17 cells against HIV in a paracrine fashion. Indeed, addition of a cocktail of exogenous MIP-1␣, MIP-1␤, and RANTES at 100 ng/ml each was needed to protect the Th17 cells by Ͼ50% (28) . In contrast, transfection with MIP-1␤ was effective in reducing infection by Ͼ80%, even though MIP-1␤ levels in supernatants were only 0.6 ng/ml. The potency of the autocrine CCR5 ligands can be explained by a recent work depicting a virus entry model in which, while HIV binding to CD4 takes place on the cell surface, CCR5 engagement is likely to occur inside endosomal compartments, into which the virus is rapidly internalized and where the fusion events proceed after a set time delay (42) . Hence, blockage of infection by the CCR5 ligands would be most effective when these chemokines are synthesized in an autocrine fashion and efficiently reach the internal virus-fusion compartments.
Once HIV infection is established in CD4 T cells, massive cell death ensues by apoptotic and pyroptotic mechanisms (43, 44) . While apoptosis is triggered through either extrinsic or intrinsic pathways where caspase 3 activation is a common event, pyroptosis is induced by caspase 1 activation (45, 46) . In our study, HIVinfected cultures of CCR6 ϩ cells were more prone to both apoptosis and pyroptosis than infected CCR6 Ϫ cells. Increased cell death and depletion among CCR6 ϩ Th17 cells was a result of direct virus infection, since it was abrogated by virus inactivation and required infection with HIV bearing functional Nef or Vpr (28) (data not shown). We also observed no bystander effects from soluble factors or neighboring infected cells that could ac-count for the loss of Th17 cells during HIV infection. Further studies to better define the specific proteins and pathways involved in activating apoptosis and pyroptosis in HIV-infected Th17 cells are needed in order to find novel drugs inhibiting the activity of these viral factors and preserving Th17 responses in chronically infected patients.
This study introduced an in vitro culture system of human CD4 T cells that allows us to investigate Th17 cells, an important component of the immune system which is highly susceptible to HIV. A combination of unique characteristics was defined that correlated with greater susceptibility of these Th17 cells to infection and cell death by CCR5-tropic and CXCR4-tropic HIV. By defining the factors contributing to Th17 depletion during HIV infection, this study advances our understanding about HIV pathogenesis for the development of more effective prophylactics and therapeutics against HIV.
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